Intravenous bortezomib for multiple myeloma that has progressed after subcutaneous bortezomib therapy

被引：3
|
作者：
Kuroda, Junya [1 ]
Mizutani, Shinsuke [1 ]
Shimura, Yuji [1 ]
Maegawa, Saori [1 ]
Nagoshi, Hisao [1 ]
Chinen, Yoshiaki [1 ]
Tatekawa, Shotaro [1 ]
Tsukamoto, Taku [1 ]
Mizuno, Yoshimi [1 ]
Yamamoto-Sugitani, Mio [1 ]
Kobayashi, Tsutomu [1 ]
Matsumoto, Yosuke [1 ]
Horiike, Shigeo [1 ]
Taniwaki, Masafumi [1 ]
机构：
[1] Kyoto Prefectural Univ Med, Dept Med, Div Hematol & Oncol, Kamigyo Ku, Kyoto 6028566, Japan
来源：
ANNALS OF HEMATOLOGY | 2015年 / 94卷 / 04期
关键词：
RESISTANCE;
D O I：
10.1007/s00277-014-2214-x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：687 / 689
页数：3
相关论文
共 50 条
  • [31] RENAL FAILURE IS REVERSIBLE AFTER THERAPY WITH BORTEZOMIB IN PATIENTS WITH MULTIPLE MYELOMA
    Goranova-Marinova, V.
    Nedeva, A.
    Nikolov, I.
    Georgiev, P.
    Hristova, I.
    Gigov, I.
    Raynov, J.
    Goranov, S.
    HAEMATOLOGICA, 2013, 98 : 602 - 603
  • [32] SUBCUTANEOUS BORTEZOMIB IN PATIENTS OVER 75 YEARS WITH MULTIPLE MYELOMA
    Violeta, Martinez-Robles
    Belen, Ballina
    Seila, Cerda
    Filomeno, Rondon
    Natalia, De Las Heras
    Jose-Antonio, Rodriguez-Garcia
    Fernando, Escalante
    HAEMATOLOGICA, 2016, 101 : 302 - 302
  • [33] DOMESTIC SUBCUTANEOUS SELF-INJECTION OF BORTEZOMIB IN MULTIPLE MYELOMA
    Cerchione, C.
    Nappi, D.
    Migliaccio, I.
    Salvatore, D.
    Pane, F.
    Catalano, L.
    HAEMATOLOGICA, 2016, 101 : 801 - 801
  • [34] Dorsal Column Degeneration after Bortezomib Therapy in a Patient with Multiple Myeloma
    Joh, Tatsuro
    Sigematu, Kazuto
    Yasui, Jun-Ichi
    Takasaki, Yumi
    Tawara, Masayuki
    Takahara, Osamu
    Tomonaga, Masao
    CASE REPORTS IN ONCOLOGY, 2009, 2 (03): : 184 - 188
  • [35] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Tomohiko Kamimura
    Toshihiro Miyamoto
    Shuichiro Takashima
    Noriko Yokota
    Yong Chong
    Yoshikiyo Ito
    Koichi Akashi
    International Journal of Hematology, 2012, 96 : 525 - 527
  • [36] ESTIMATING THE BUDGET IMPACT OF SWITCHING FROM BORTEZOMIB INTRAVENOUS (IV) TO BORTEZOMIB SUBCUTANEOUS (SQ) IN THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM) IN MEXICO
    Wehler, E. A.
    Kowal, S.
    Hernandez-Garduno, A.
    Danese de los Santos, L.
    de Anda, J. A.
    Anaya, P.
    Munakata, J.
    Gonzalez, L.
    VALUE IN HEALTH, 2015, 18 (07) : A818 - A818
  • [37] Injection site reaction after subcutaneous administration of bortezomib in Japanese patients with multiple myeloma
    Kamimura, Tomohiko
    Miyamoto, Toshihiro
    Takashima, Shuichiro
    Yokota, Noriko
    Chong, Yong
    Ito, Yoshikiyo
    Akashi, Koichi
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (04) : 525 - 527
  • [38] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
    J R Berenson
    J D Hilger
    O Yellin
    R Dichmann
    D Patel-Donnelly
    R V Boccia
    A Bessudo
    L Stampleman
    D Gravenor
    S Eshaghian
    Y Nassir
    R A Swift
    R A Vescio
    Leukemia, 2014, 28 : 1529 - 1536
  • [39] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy
    Berenson, J. R.
    Hilger, J. D.
    Yellin, O.
    Dichmann, R.
    Patel-Donnelly, D.
    Boccia, R. V.
    Bessudo, A.
    Stampleman, L.
    Gravenor, D.
    Eshaghian, S.
    Nassir, Y.
    Swift, R. A.
    Vescio, R. A.
    LEUKEMIA, 2014, 28 (07) : 1529 - 1536
  • [40] Low dose intravenous melphalan and bortezomib for relapsed multiple myeloma
    Popat, R
    Oakervee, HE
    Foot, N
    Agrawal, S
    Odeh, L
    Craddock, C
    Williams, C
    Basu, S
    Williams, C
    Basu, S
    Cavenagh, JD
    BRITISH JOURNAL OF HAEMATOLOGY, 2006, 133 : 98 - 98
12345